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Quantitative proteomic analysis with mass spectrometry holds great promise for simulta-
neously quantifying proteins in various biosamples, such as human plasma. Thus far, stud-
ies addressing the reproducible measurement of endogenous protein concentrations in
human plasma have focussed on targeted analyses employing isotopically labelled stan-
dards. Non-targeted proteomics, on the other hand, has been less employed to this end,
even though it has been instrumental in discovery proteomics, generating large datasets in
multiple fields of research.
Results
Using a non-targeted mass spectrometric assay (LCMSE), we quantified abundant plasma
proteins (43 mg/mL—40 ug/mL range) in human blood plasma specimens from 30 healthy
volunteers and one blood serum sample (ProteomeXchange: PXD000347). Quantitative
results were obtained by label-free mass spectrometry using a single internal standard to
estimate protein concentrations. This approach resulted in quantitative results for 59 pro-
teins (cut off11 samples quantified) of which 41 proteins were quantified in all 31 samples
and 23 of these with an inter-assay variability of 20%. Results for 7 apolipoproteins were
compared with those obtained using isotope-labelled standards, while 12 proteins were
compared to routine immunoassays. Comparison of quantitative data obtained by LCMSE
and immunoassays showed good to excellent correlations in relative protein abundance (r
= 0.72–0.96) and comparable median concentrations for 8 out of 12 proteins tested. Plasma
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concentrations of 56 proteins determined by LCMSE were of similar accuracy as those
reported by targeted studies and 7 apolipoproteins quantified by isotope-labelled standards,
when compared to reference concentrations from literature.
Conclusions
This study shows that LCMSE offers good quantification of relative abundance as well as
reasonable estimations of concentrations of abundant plasma proteins.
Introduction
Mass spectrometry (MS) based proteomics has various useful roles in both (clinical) research
and routine diagnostics [1]. To date, clinical researchers have exploited the ability of proteo-
mics to generate information-rich datasets of proteins, protein modifications, and potential
biomarkers in various body fluids and other patient materials. This type of discovery proteo-
mics usually consists of ‘bottom-up’ proteomics in which protein samples are digested by pro-
teases and resulting peptides are used for identification and quantification of the constituent
proteins. It routinely uses many stages of protein and peptide fractionation to generate a great
number of protein identification and quantitative data and is thus inherently time consuming.
Recently, targeted proteomics-techniques have been in the spotlight in clinical proteomics,
promising rapid simultaneous measurement of multiple proteins at low setup cost [2, 3]. This
could alleviate bottlenecks for validating large numbers of candidate biomarkers generated in
discovery proteomics in readily accessible bodily fluids like plasma. Because of this promise
various studies compare plasma protein concentrations determined by targeted proteomics
assays [4–11] to more routine clinical immunoassays and find correlations that range from low
[5] (r = 0.43 for myeloperoxidase) to reasonable and excellent [4–11] (r = 0.63–0.99). Refine-
ments in assay development and improved mass spectrometric techniques make the the plasma
proteome of high to moderate concentration (mg/mL to ng/mL range) currently accessible
without prior enrichment or fractionation [12–18]. As an example: Percey et al. reported the
reproducible simultaneous analysis of 142 proteins with an analysis time of only ~47 minutes
in non-depleted and non-enriched human plasma [15].
In contrast to targeted proteomic techniques, non-targeted proteomic approaches have so
far not been tested with respect to their ability to quantify protein concentrations in clinically
relevant sample matrices. This could be due to the fact that using isotope-labelled standards for
each protein (as done in targeted proteomics) is impractical and costly, as illustrated by the
limited number of targeted studies attempting to quantify larger protein sets using these stan-
dards. In discovery proteomics various approaches to estimate protein abundance in samples
without such isotope-labelled standards have been developed. These entail either peptide or
spectral counting. Examples are: EMPAI [19, 20] and APEX [21, 22], or precursor intensity
based methods, such as iBAQ [23] and HI3/TOP3 peptide quantification [24, 25]. Several of
these approaches have been compared in their ability to accurately determine relative or abso-
lute protein abundance in different sample matrices [26–28]. HI3 peptide quantification, uses
the sum of signal intensities of the three best ionizing peptides of any given protein and com-
pares this to the sum of a reference protein digest spiked at a known concentration to estimate
protein abundance. Protein concentrations determined by this method compare reasonably
well with reference ranges in human sera [24]. Furthermore, we previously also used the HI3
peptide approach to quantify changes in the concentrations of abundant proteins in sera of
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Gaucher patients [29]. In this study the analysis of sera (both immuno-affinity depleted and
full serum) of a small cohort of Gaucher patients showed corrections in abundant serum pro-
teins upon treatment of patients with enzyme replacement therapy and good correlations
between HI3 peptide quantitation of chitotriosidase (an important Gaucher disease biomarker)
and a chitoriosidase activity assay used in routine diagnosis and disease monitoring.
In order to characterize how well HI3 peptide quantitation estimates protein concentrations
in a complex sample matrix, we set out to evaluate its performance in human plasma. To do so,
plasma protein concentrations are assayed by HI3 peptide quantitation and compared to those
obtained using isotope-labelled standards for 7 apolipoproteins. In addition, the HI3 quantita-
tion of plasma protein concentrations (in a cohort of 31 healthy volunteers) are compared
against reference ranges and routine immunoassays conducted in parallel. The results of our
investigations are presented and the potential use of non-targeted proteomics in quantitation
of abundant plasma proteins is discussed.
Materials and Methods
Plasma Samples
Samples were obtained via the annual blood collection from healthy volunteers to prepare stan-
dard pooled plasma for diagnostic coagulation, other assays and individual plasma samples for
research purposes. This is approved by the Ethical Committee at the Academic Medical Center,
University of Amsterdam. Volunteers entered the blood collection event after a general call in
the hospital newspaper and signed informed consent in accordance with the declaration of
Helsinki. Blood samples were obtained from 31 healthy volunteers, selected from the 200 vol-
unteers participating, individually tested for the presence of HIV, hepatitis B and C prior to the
blood collection and excluded if one of the tests proved positive. This resulted in 17 males and
14 females with a median age of 46 years and a range of 22–67 years. The 30 human blood
plasma samples were anonymized and had a balanced gender (16 males, 14 females) and age
distribution (5–6 samples in each of the age categories 20–30, 31–40, 41–50, 51–60 and 61–70
years of age). Blood was obtained by venepuncture in 4 ml blood collection tubes (Becton Dick-
inson Franklin Lakes, NJ) in a final concentration of 17 IU/ml lithium-heparin. Samples were
centrifuged within 15 minutes at 1780 g at 4° for 10 minutes. The plasma was then collected,
divided in aliquots of 1 ml and stored at -80° within 15 minutes. The average time from collec-
tion to storage was 40 minutes. The 31st sample was a serum sample (clotting time 20 minutes
followed by centrifugation at 2000 x g at 4° for 10 minutes) we processed for comparison with
the results in the heparinized plasma. As results were completely comparable, the serum sam-
ple was also included in the analyses. Before use, samples were thawed at room temperature.
Clinical Assays, reference range and assay range
Samples were processed as described above, concentrations of ceruloplasmin and serum albu-
min were determined nephelometrically on a BN-Prospec (Siemens, Tarrytown, NY) after
immuno-complexation with their respective antisera (Siemens). Concentrations of haptoglo-
bin, immunoglobulins alpha, gamma and mu as well as serotransferrin were determined by
turbidity measurements on a Modular P800 analyzer (Roche, Basel, Switzerland) following
immuno-complexation with their respective Tina-Quant antisera (Roche). After immuno-
complexation with their respective antisera (Abbott, Chicago, IL), concentrations of Comple-
ment C3, C4 and apolipoproteins A1 and B-100 were determined by turbidity measurements
on an ARCHITECT ci8200 (Abbott). Fibrinogen concentration was determined by measuring
plasma clotting using a thrombin reagent (Siemens) on a Sysmex CA-7000 (Siemens). Refer-
ence and assay ranges are given in Table 1 for the different assays employed.
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Sample preparation for LC-MS analysis
Total plasma protein concentration was assayed with a BCA-assay [30] according to the manu-
facturer’s protocol (Thermo). Samples were diluted tenfold in 0.1% Rapigest SF (Waters Cor-
poration, Milford, MA), 50 mM ammonium bicarbonate and heated at 95°C for 15 min.
Subsequently, plasma samples were reduced with 5 mM dithiothreitol (60°C, 30 min) and
alkylated with 15 mM iodoacetamide (ambient temperature, dark, 30 min). Proteolytic diges-
tion was performed with modified trypsin (gold grade, Promega, Madison WI) at 0.3 units/μg
protein, (37°C, 20 hours) unless indicated otherwise. Following digestion, Rapigest SF was bro-
ken down by adding 1% trifluoroacetic acid (pH<2, 37°C, 45 min). Peptide solutions were cen-
trifuged (20,000 x g, 10 min) and supernatant was collected. Prior to analyses a MASSPREP
protein digestion standard (Waters Corporation, ADH1 or ENO from Saccharomyces cerevi-
siae) was added for quantitation purposes. LC-MS analyses were performed using ~ 0.21 μg of
the final plasma protein digest mixtures (384 times total dilution) unless indicated otherwise.
LC-MS analysis
Nanoscale LC separations of tryptic peptides were performed with a NanoAcquity system
(Waters Corporation). Samples were loaded onto a Symmetry C18 5 μm, 2 cm x 180 μm trap
column (Waters Corporation) at a flow rate of 5 μl/min prior to separation on a Bridged Ethyl
Hybrid C18 1.7 μm, 25 cm x 75 μm analytical reversed phase column (Waters Corporation) by
application of a 90 minute gradient from 1% acetonitrile, 0.1% formic acid to 40% acetonitrile,
0.1% formic acid at a column flow rate of 0.250 μl/min. Analysis of eluting tryptic peptides was
performed using a Synapt G2 quadrupole time of flight mass spectrometer (Waters Corpora-
tion, Manchester, UK) equipped with a nanolockspray source (Waters Corporation) fitted with
a pico-tip emitter (New Objective, Woburn, MA). Operated values: around 3 kV capillary volt-
age, cone voltage of 40 V, a source temperature of 90°C and TOF-voltage set at 7 kV. The colli-
sion gas used was argon, maintained at a constant pressure of 2.0x10-3 mbar in the collision
cell. The lock mass, [Glu1]-Fibrinopeptide B, was delivered from the auxiliary pump of the
NanoAcquity system at a concentration of 100 fmol/μl at 0.5 μl/min to the reference sprayer of
the nanolockspray source which was sampled every 120 seconds. The data were post-acquisi-
tion lock-mass corrected using the monoisotopic mass of the doubly charged precursor of
Table 1. Reference and assay ranges clinical assays.
Assay Reference range (x106 ng/mL) Assay range1 (x106 ng/mL)
Albumin 35–50 2–60
Immunoglobulin Gamma 7.0–16.0 3.0–50.0
Serotransferrin 2.0–3.6 0.10–5.2
Fibrinogen 1.5–4.0 0.3–10.0
Complement C3 0.9–1.8 0.03–3.32
Apolipoprotein A-I 1.0–2.1 0.03–3.32
Haptoglobin 0.3–2.0 0.1–5.7
Apolipoprotein B-100 0.55–1.2 0.03–2.76
Immunoglobulin Alpha 0.7–4.0 0.5–8.0
Complement C4 0.1–0.4 0.01–0.8
Ceruloplasmin 0.20–0.55 0.07–2.20
Immunoglobulin Mu 0.40–2.3 0.25–6.50
1Assay ranges are provided by the respective manufacturers.
doi:10.1371/journal.pone.0140097.t001
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[Glu1]-Fibrinopeptide B. Accurate mass precursor and fragment ion LC-MS data were col-
lected in data independent LCMSE mode of acquisition [31] in the “resolution mode” of the
instrument (i.e.20,000 resolution at full width half maximum at 785.84 m/z). System perfor-
mance was monitored by regular injections of 50 fmol ADH1 MASSPREP protein digestion
standard (Waters Corporation, from S. cerevisiae). Total peptide signal intensity, retention
time accuracy and chromatographic resolution were monitored and generally kept70% of
starting intensity, within 1% of retention time variation and within 10 seconds full width half
maximum mean chromatographic peak width, respectively (system performance was assayed
on a shorter 30 min gradient 0–40% acetonitrile and 0.1% formic acid).
Data processing and protein identification
Continuum LC-MS data were processed using ProteinLynx GlobalSERVER version 2.5 (PLGS
2.5, Waters Corporation). Parameter settings: digest reagent trypsin, allow 1 ‘missed cleavage’,
search tolerances automatic, typically 5 ppm for precursor and 15 ppm for product ions, fixed
modification cysteine carbamidomethylation, and variable modification methionine oxidation.
Protein identifications were obtained searching the human SwissProt entries of a UniProt data-
base (release 13.2). This database was modified to include N-terminal processing of proteins
using protein maturation device software [32, 33], with ADH1 and ENO1 of S. cerevisiae
appended as internal standard to address technical variation and allow concentration determi-
nations. Estimation of false-positive identification rates was done by searching a randomized
version of the abovementioned human protein database generated within PLGS 2.5. Data were
exported as csv-files for further, detailed analysis.
Stringent criteria were applied for quantitation, protein identifications were only consid-
ered significant if reported in 11 or more samples. Protein false positive identification rates
were estimated using the criteria mentioned above and no false positives were identified in
these searches. This resulted in the identification of 77 database entries (using 1498 peptide
sequences). Of these 11 entries containing highly variable regions of immunoglobulins were
filtered out (S1 Table).
HI3 peptide quantitation
Label free quantitation of proteins is based on the sum of the signal intensities of the three
most abundant peptides (as defined by the precursor ion area under the chromatographic
peak) of a protein, (HI3(protein)) divided by the sum of the signal intensities of the three most
abundant peptides of the internal standard, (HI3(standard)) times the amount in fmol of stan-
dard injected on the column [24] (Eq 1).
HI3ðproteinÞ
HI3ðstandardÞ  fmol standardÞ ð1Þð
This gives an estimation of the molar amount of each protein injected on the column and
PLGS 2.5 determines the molar amount (the amount in ng is determined using the molecular
weight in the database) for each protein based on the ratio of its most abundant peptides deter-
mined in each individual experiment. These protein amounts determined were used for pro-
teins that met the criteria for confident identification indicated above, to calculate the average
concentration of each protein in g/L using the dilution factor of the samples. For some proteins
(IgG, IgA, fibrinogen and complement C4), values of constituent polypeptide-chains were
summed to obtain the protein values (see S1 Text.).
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Determination of linearity, LOD/LOQ, digestion efficiency and assay
variability
To determine the amount of plasma digest to load onto a column in order for measurements to
be in the linear range, a pooled plasma digest was diluted with 0.1% trifluoroaceticacid and
mixed with equal amounts of internal standard (ADH1) prior to LCMSE analysis and HI3 pep-
tide quantitation. Ordinary least square linear regression was used to ascertain whether there
was a linear correlation between protein amount loaded and protein amount quantified on col-
umn. From the dilution series the lowest amount (ngram) detected on column was calculated
into g/L using the dilution factor (320x) of a 250 ng column load. This value, i.e. the limit of
quantitation (LOQ), is reported in Table 2. As shown in S4 Fig, proteins quantified and pro-
teins detected almost completely overlap in LCMSE analysis of plasma, and as such, the lowest
amount quantified on column is close to the limit of detection (LOD) as well. To test for diges-
tion efficiency, a time series up to 24 hours of digestion is shown in S2 Fig panels a through c at
0.3 units trypsin per ug of protein. The summed HI3 peptide signals were adjusted for changes
in ionisation efficiency by adjusting for the summed signals of all proteins detected. Values
shown are relative to the highest summed HI3 peptide signal measured during the time series
for each individual protein plotted. To ascertain which proteins change significantly in total
amount quantified when using higher amounts of trypsin, a 20 hour digestion was performed
with 0.15, 0.3 and 0.75 units of trypsin per ug of protein and reported in S2 Table. Assay vari-
ability was monitored by analysis of aliquots of a pooled plasma sample. The analytical vari-
ance (AV, Table 2) was calculated throughout 9 days of LCMSE measurements by 10 repeated
injections of a single plasma digest (n = 1). Intra-assay variation (IAV, Table 2) was determined
by 6 individual digestions of aliquots of a pooled plasma sample (n = 6) and measurements
during a single day. Inter-assay variability (IRV, Table 2) was determined by freezing 7 aliquots
of a pooled plasma sample and thawing, digesting and measuring these over a 3 month period
of normal operation of the instrument.
QconCAT production and purification
The QconCAT protein (sequence below) was produced as previously described [34] using cell
lysis by sonication and purified by Ni-MAC nickel affinity column (Novagen, Merck Milli-
pore). The QconCAT concentration was assayed with a BCA-assay [30] according to the man-
ufacturer’s protocol (Thermo).







QconCAT standard was spiked into pooled plasma samples prior to digestion as described in
thematerials and methods section at the amounts indicated (25–250 fmol/ul in a background
of 250 ng/ul plasma and 50 fmol/ul ADH1 digest standard). LCMSE data were acquired as
described above and continuum LC-MS data were processed using ProteinLynx GlobalSER-
VER version 2.5. Parameter settings were as described above with additional variable modifica-
tions: 13C6-Lysine (+6.0209 amu) and
13C6-Arginine (+6.0209 amu). Data were exported as
Plasma Protein Quantification by Mass Spectrometry
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Table 2. Hi3 peptide quantitative analysis of abundant plasma proteins. (50:1 substrate:enzyme, 20 hours digestion, 0.21 ug on column injection).
No Protein name median (ng/mL) IRV IAV AV LIN ST LOQ n FN
1 Albumin 7.4 x107 12 15 11 0.992 0.955 6.0 x103 31 1
2 Ig gamma 4.8 x106 30 17 5 0.985 0.998 8.5 x104 31 2
3 Serotransferrin 2.7 x106 19 19 9 0.991 0.976 2.6 x105 31 3
4 Fibrinogen 2.6 x106 14 15 9 0.995 0.991 7.0 x104 30 4
5 Complement C3 2.3 x106 17 16 7 0.987 0.974 5.6 x104 31 5
6 Alpha-2-macroglobulin 1.8 x106 16 11 4 0.990 0.993 5.2 x104 31 6
7 Apolipoprotein A-I 1.7 x106 29 14 8 0.991 0.976 2.2 x104 31 7
8 Alpha-1-antitrypsin 1.6 x106 14 16 15 0.985 0.964 2.7 x104 31 8
9 Haptoglobin 1.3 x106 26 20 9 0.993 0.991 3.2 x104 31 9
10 Ig kappa chain C region 1.0 x106 25 14 8 0.989 0.985 1.7 x104 31 10
11 Apolipoprotein B-100 9.7 x105 14 15 9 0.966 0.999 2.5 x105 31 11
12 Hemopexin 9.1 x105 12 12 4 0.999 0.960 2.1 x104 31 12
13 Ig alpha 7.3 x105 18 17 8 0.998 0.982 2.3 x104 31 13
14 Complement C4 6.8 x105 16 16 14 0.979 - 1.3 x105 31 14
15 Fibronectin 5.0 x105 - - 32 - - - 22 15
16 Ig lambda chain C region 4.0 x105 22 17 7 0.989 0.976 1.5 x104 31 16
17 Ceruloplasmin 3.5 x105 22 16 8 0.990 0.992 1.8 x104 31 17
18 Inter-alpha-trypsin inhibitor hc H2 3.5 x105 14 18 14 0.991 0.965 2.4 x104 31 18
19 Complement factor H 2.7 x105 20 20 5 0.991 0.990 3.3 x104 31 19
20 Vitamin D-binding protein 2.7 x105 15 15 9 0.994 0.993 3.3 x104 31 20
21 Kininogen-1 2.6 x105 17 14 10 0.989 0.963 3.6 x104 31 21
22 Alpha-2-HS-glycoprotein 2.4 x105 16 13 12 0.990 0.961 4.0 x103 31 22
23 Plasminogen 2.2 x105 22 20 11 0.991 0.983 4.7 x104 31 23
24 Ig mu chain C region 2.2 x105 26 14 17 0.993 0.997 1.4 x104 31 24
25 Apolipoprotein A-II 2.0 x105 27 17 6 0.995 0.988 2.4 x104 31 25
26 Alpha-1-antichymotrypsin 1.8 x105 16 6 6 0.989 0.961 6.0 x103 31 26
27 Inter-alpha-trypsin inhibitor hc H1 1.8 x105 16 - 18 0.993 - 4.4 x104 31 27
28 Alpha-1-acid glycoprotein 1 1.7 x105 41 16 10 0.990 0.971 6.0 x103 31 28
29 Beta-2-glycoprotein 1 1.7 x105 11 31 7 0.993 0.966 7.2 x104 31 29
30 Inter-alpha-trypsin inhibitor hc H4 1.7 x105 43 10 7 0.993 0.995 2.0 x104 31 30
31 Complement factor B 1.5 x105 25 52 11 0.995 0.974 2.5 x104 31 31
32 Clusterin 1.5 x105 10 17 10 0.990 0.958 1.7 x104 31 32
33 Alpha-1B-glycoprotein 1.4 x105 18 12 9 0.989 0.955 1.0 x104 31 33
34 Prothrombin 1.4 x105 16 23 51 0.993 0.974 1.7 x104 31 34
35 Antithrombin-III 1.4 x105 20 19 7 0.984 0.962 5.0 x103 31 35
36 Plasma protease C1 inhibitor 1.3 x105 19 18 10 0.964 0.966 1.1 x104 31 36
37 Vitronectin 1.1 x105 13 13 10 0.995 0.982 1.4 x104 28 37
38 Apolipoprotein A-IV 1.0 x105 18 16 9 0.994 0.972 9.0 x103 31 38
39 C4b-binding protein alpha chain 1.0 x105 18 13 35 0.996 0.997 1.5 x104 31 39
40 Histidine-rich glycoprotein 9.0 x104 21 13 10 0.976 0.958 8.0 x103 31 40
No Protein name median (ng/mL) IRV IAV AV LIN ST LOQ n FN
41 Gelsolin 7.0 x104 23 36 11 0.990 - 3.5 x104 22 41
42 Heparin cofactor 2 6.6 x104 17 - 100 0.991 - 1.1 x104 11 42
43 Afamin 5.7 x104 16 12 15 0.998 0.954 1.0 x105 18 43
44 Angiotensinogen 5.7 x104 19 16 5 0.989 0.992 1.1 x104 30 44
45 Paraoxonase/arylesterase 1 5.1 x104 22 - 22 0.982 0.999 7.0 x103 23 45
46 Alpha-1-acid glycoprotein 2 5.0 x104 44 15 13 0.999 0.958 4.0 x103 31 46
(Continued)
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csv-files and precursor ion intensities (area under the chromatographic peak) of both endoge-
neous (apolipoprotein-derived) and heavy labelled (QconCAT-derived) peptides were
extracted. The amount of protein in fmol was calculated as shown in Eq 2.
Ion intensityðendogeneous peptideÞ
Ion intensity ðQconCAT peptideÞ  fmol QconCATÞ ð2Þð
The amount obtained in fmol was subsequently used with the proteins molecular weight
and sample dilution factor (320x) to calculate the plasma protein concentration in ng/mL for
each peptide detected. The average plasma protein concentration of each protein was calcu-
lated by taking the average value of two peptides when available, or the single peptide value if
only one of two peptides was detected. The intra-assay CV (IAV) and average protein concen-
tration reported in S8 Table were calculated from 5 pooled plasma samples. These samples
were spiked with 100 fmol/ul QconCAT (250 ng/ul plasma and 50 fmol/ul ADH1 digest stan-
dard) and measured within one day to obtain the reported values.
Results and Discussion
Introducing HI3 peptide quantitation and estimating its linear response
range for plasma
We assayed how well quantitative results obtained by non-targeted HI3 peptide quantitation
compare to those obtained by other analytical approaches such as immunoassays and proteo-
mic approaches using isotope-labelled standards. HI3 peptide quantitation uses a reference
digest standard to estimate absolute amounts of all proteins in a sample as described in Eq 1.
As such, different internal digest standards should give similar responses for their HI3 peptide
Table 2. (Continued)
47 Hemoglobin subunit alpha 4.1 x104 40 - 7 0.991 - 3.0 x103 31 47
48 Apolipoprotein C-III 3.9 x104 32 27 20 - 0.978 1.4 x104 31 48
49 Protein AMBP 3.9 x104 26 10 16 0.825 0.949 7.0 x103 22 49
50 Hemoglobin subunit beta 3.8 x104 17 42 8 0.992 0.983 4.0 x103 31 50
51 Pregnancy zone protein 3.6 x104 64 64 75 0.959 0.998 7.0 x103 15 -
52 Zinc alpha 2 glycoprotein 3.3 x104 24 12 212 0.772 0.971 4.0 x103 20 51
53 Apolipoprotein E 3.1 x104 19 6 11 0.996 0.964 1.7 x104 27 52
54 CD5 antigen like protein 2.5 x104 8 7 15 - 0.997 1.3 x104 19 -
55 Haptoglobin-related protein 2.3 x104 24 24 21 0.968 0.995 3.0 x103 16 53
56 Retinol-binding protein 4 2.2 x104 20 - 27 - - - 14 54
57 Apolipoprotein D 2.1 x104 - - 13 - - - 20 55
58 Apolipoprotein C-I 1.6 x104 - - 11 - - - 26 56
59 Apolipoprotein C-II 1.6 x104 - 23 7 - 0.922 - 19 57
Median (ng/mL): median of protein concentrations determined from number of samples shown in column n. IRV: inter-assay variation, the coefficients of
variation obtained from 7 aliquots of a pooled sample separately digested and measured over the course of 3 months of normal operation of the
instrument. IAV: intra-assay variation, coefficient of variation obtained from 6 aliquots of a pooled sample separately digested and subsequently measured
during 1 day. AV: analytical variability, determined from 10 replicate injections of a single digested sample throughout 9 days of measurements. LIN:
linearity of measurements, the Pearson’s correlation coefficient shows linearity between total protein load on the analytical column and nanogram protein
quantified by HI3 peptide quantitation using the ADH1 digest standard; only determined when at least 4 points were available for a protein. See also S1
Fig. ST: Pearson’s correlation of protein quantitation using two different digest standards (ADH1 and ENO1 from yeast). LOQ: limit of quantitation (ng/mL)
estimated by dilution of a plasma sample in a constant background of a digest standard. n: number of samples (out of 31) in which the protein was
quantified, FN: protein number on the x-axis of Fig 1c. hc: heavy chain.
doi:10.1371/journal.pone.0140097.t002
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summed signal intensities as reported before [24]. Fig 1a shows that two different digest stan-
dards (ADH1 and ENO1) spiked into a plasma background at different concentrations give a
highly similar response. Furthermore, it shows that the amount of internal digest standard
used (50 fmol on column) in the HI3 peptide quantitation falls within the linear response
range. The relative amounts of albumin quantified for 17 plasma samples using ADH1 or
ENO1 as spiked standard are highly similar, as shown in Fig 1b. Table 2 shows the Pearson’s
correlation coefficient (ST) for relative quantitation using ADH1 or ENO1 as internal standard
of 50 plasma proteins (out of 59 in Table 2) is> 0.92. A small systemic difference persists, as
absolute amounts estimated with ENO1 are 1.46 (SD 0.06) times higher than when ADH1 is
used.
To determine that the total amount of plasma digest loaded onto the column is also in the
linear response range, an increasing amount of plasma digest was injected (0.01–1.0 μg total
protein). S1 Fig shows that the response was linear within this range for a subset of abundant
proteins and Table 2 shows linearity (LIN) for the vast majority of proteins measured
(r> 0.95). The total amount of protein loaded (~ 0.21 μg) during analysis falls within this
range of linear response. In addition the limit of quantitation (LOQ) was estimated by diluting
plasma in a constant background of digest standard and calculating the concentration that was
still quantified in multiple injections of the dilution series (Table 2).
Experimental variables influencing HI3 peptide quantitation: conditions
of tryptic digestion
LCMSE uses peptides as proxies for calculation of amounts of intact proteins; variation in
digestion efficiency for proteins can have a profound impact on quantitation results while
obtaining a complete digestion for all proteins is unlikely [4, 35–37]. To estimate which incuba-
tion time would ensure the most complete digestion for most proteins, a time series (1, 2, 3, 4,
5, 6, 7, 8, 16, 20 and 24 hrs) was performed at 0.3 units trypsin/μg protein with an MS-compati-
ble surfactant (Rapigest SF) to aid digestion. The HI3 peptide quantitation at different time
points is shown in S2 Fig panels a through c for 52 proteins that were reproducibly detected.
Most proteins (S3 Fig panels a and b) show early maximisation of HI3 peptide signals within
1–2 hours of incubation with trypsin, with no or minor changes up to 24 hours of digestion.
On the other hand a group of 16 proteins (S3 Fig panel c) show a definite increase of HI3 pep-
tide signals with prolonged incubation times, indicating that these proteins require longer
digestion times to reach their maximal HI3 peptide quantitation value. Amongst the proteins
requiring longer digestion times 7 apolipoproteins are found. This is not surprising in light of
their association in lipoprotein particles in plasma and was previously observed [4]. To test
whether amounts of trypsin added significantly influences the absolute amount quantified,
plasma was incubated with 0.15, 0.3 or 0.75 units per μg of total protein for 20 hours (1:100, 50
or 20 protease to protein ratio respectively). The addition of increasing amounts of trypsin
does not result in significantly altered quantitation, as the majority of proteins (45 out of 52)
detected show a change in quantitation of less than 1.5 fold (S2 Table). Given these results, we
decided to employ a digestion time of 20 hours with 0.3 units trypsin per μg of total protein.
Here we chose for an in solution digestion protocol aided by an acid labile surfactant (Rapi-
gest SF) to enhance protein unfolding and tryptic digestion, as a recent assessment of digestion
protocols [37] showed that surfactant aided in solution protocols (among which Rapigest SF)
performed similarly or better than filter aided digestion approaches [38, 39] on a (mitochon-
drial) protein preparation. In this study a protocol based on deoxycholate (less expensive than
Rapigest SF) and phase separation rather than acid precipitation showed the best performance
both in protein numbers and reproducibility. This suggests that the current approach could
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Fig 1. HI3 peptide quantitation with a single protein digest standard and digest standard comparison. (a) Summed signal intensity of the protein
digest standard ENO1 (grey square) and ADH1 (dark grey circle) added at increasing concentrations to a plasma digest. (b) Quantitation of albumin using
either ENO1 or ADH1 as the internal standard in 17 indivual samples. The regression line (solid black) and its formula, obtained by ordinary least squares
linear regression, is depicted, with the dashed line representing perfect correlation. (c) 57 proteins from Table 2 for which reference ranges from literature
were available, are ordered according to their median concentration determined by HI3 peptide quantitation (dark grey squares, quantified in 11 out of 31
samples). Error bars indicate the minimal and maximum value measured in the plasma samples. The reference ranges (grey boxes) are taken from Hortin
et al. [42]. Protein no. correspond to the numbers given in Table 2.
doi:10.1371/journal.pone.0140097.g001
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also benefit from this protocol at least in terms of reproducibility if not in increase of numbers
of proteins quantified. Another recent report applies a digestion protocol that depletes abun-
dant proteins in S. cerevisiae by differential digestion, called DigDeAPr [40, 41]. This could
potentially increase the depth of coverage of the plasma proteome in a fashion not dissimilar
from depletion of abundant plasma proteins by antibody based capture columns. This
approach promises a more unbiased depletion and could certainly be useful in increasing the
depth of coverage of the plasma proteome for both untargeted and targeted proteomics
approaches when doing comparative studies. However, in the current study, where we also try
to compare the accuracy of concentration values with regard to reference ranges it is of course
counterproductive to alter protein abundancies.
Comparing HI3 peptide quantitation to reported plasma reference
ranges
To ascertain the utility of non-targeted HI3 peptide quantitation in plasma, samples collected
from 31 healthy volunteers were digested and separated by reversed phase liquid chromatogra-
phy before MS detection. We quantified a total of 59 proteins (631 peptides used for HI3 pep-
tide quantitation, see S3 Table) using non-targeted LCMSE. Because PLGS 2.5 chooses the set
of HI3 peptides to use for quantification on a per sample basis, the peptides used vary from
sample to sample; for 66 database entries (59 proteins) 198 peptides would be expected if the
same three peptides would be used. On average for the measurement series ~10 peptides are
used per entry by PLGS 2.5 to construct HI3 quantification sets. As the quantitation is based
on the ratio of summed intensities of the HI3 peptides, variation in peptides used, especially for
the internal standard, can lead to variation in the absolute amount estimated by the search
algorithm. The variation in 3 most intense peptides in independent samples can have a number
of causes related to sample workup and analysis conditions.
To ascertain whether limiting this set of peptides manually would improve HI3 protein
quantitation we manually reconstructed HI3 peptide sets for 12 proteins for which we also
gathered immunoassay data (see S1 Text and S4 Table). This resulted in slight changes in
median protein concentrations (S5 Table) and lower variance for two proteins as well as
improved correlation with immunoassays for 4 proteins (see S1 Text and S5 Table). Because of
this improvement we used the manually obtained values for these proteins in all figures and
tables. However as improvement was quite limited we did not manually recalculate the values
for the remaining proteins.
With regard to the 59 proteins reported in Table 2, Hortin et al. [42] provide reference
ranges for 57 of them. Fig 1c shows the (median) plasma concentrations of these 57 proteins
determined by LCMSE (black circles) and their reference ranges (grey boxes). The large range
for complement C4 binding protein, apolipoprotein A-IV, clusterin and heparin cofactor 2 are
caused by a small number of samples (1, 3, 2 and 3 samples, respectively, see S1 Table) which
have much higher concentrations than the majority of samples in which a quantitative mea-
surement was obtained. However, as we do not have immuno-assay data for these proteins to
compare to, and inter-assay variability of these proteins<30%, this could simply represent
really elevated concentrations within these individuals rather than analytical error. Zinc alpha
2 glycoprotein on the other hand showed two distinct groups of samples of higher and lower
concentration causing the large spread of the reported range in Fig 1c.
Comparison of median protein concentrations determined by HI3 peptides and reference
ranges shows that 21 protein concentrations measured by LCMSE fall within their reference
ranges (S6 Table). Furthermore, median concentrations of 27 proteins are less than a factor
two outside of their reference ranges. Thus, only nine (of 57) proteins fall outside their
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reference ranges by more than a factor two. Three reports that use targeted proteomics and sta-
ble isotope-labelled peptides quantify large number of protein concentrations in non-depleted
and non-enriched human blood plasma. The protein concentrations reported in these studies
are compared to the protein concentrations determined by HI3 peptide quantitation and
reference ranges reported by Hortin et al. [42] in S6 Table. From the proteins reported, 23 are
quantified both by us and all three targeted studies mentioned (S7 Table). Overall the targeted
proteomics data from Kuzyk et al. [13] are comparable with HI3 peptide quantitation, as only 3
proteins (out of 23) were outside of their reference ranges by more than a factor of two com-
pared to one protein for HI3 peptide quantitation. The quantitative protein data from Domanski
et al. [16] and Percey et al. [15] showed higher discrepancies as 11 and 9 proteins, respectively,
were outside reference ranges by more than a factor of two (S7 Table).
Comparing HI3 peptide with stable isotope-labelled standard based
quantitations
Next we compared concentrations quantified by HI3 peptide quantitation and stable isotope-
labelled standards. For this we used an artificially constructed QconCAT protein expressed in
E. coli to introduce stable isotope-labelled lysine and arginine residues. This QconCAT [43], is
a concatamer of two proteotypic peptides per protein for 11 apolipoproteins. It is expressed
and purified by Ni-column chromatography and was quantified by BCA-assay to ascertain the
protein concentration (see materials and methods). The QconCAT was spiked into 5 pooled
plasma samples within the linear response range (see S4 Fig). Following tryptic digestion and
LCMSE analysis, extracted ion intensities of endogenous (apolipoprotein-derived) and isotope-
labelled peptides (QconCAT-derived) we could ascertain plasma protein concentrations for
seven apolipoproteins (Fig 2, materials and methods). The Intra-assay variability (IAV) of
quantities obtained for apolipoproteins using a QconCAT internal standard are generally
lower than those obtained by HI3 quantitation (Fig 2a). Overall the apolipoprotein concentra-
tions quantified by QconCAT are two-fold (median: 1.9, range: 1.3–3.2 fold, see S12 Table)
higher than those quantified by HI3 quantitation. As digestion and measuring conditions were
identical for these samples (QconCAT and HI3 quantitation was done within the same pooled
plasma samples), a likely reason for this offset comes from a difference in the actual amount in
fmol added of one or both standards and the value(s) used for calculation of the concentra-
tions. As mentioned in the materials and methods, the concentration of the QconCAT was esti-
mated by BCA-assay, while MASSPREP protein digestion standard amounts of ENO1 and
ADH1 are given by the manufacturer. Another possible explanation, assuming spiking in of
both standards was accurate, would be a slower release of QconCAT heavy labelled peptides
compared to endogenous light peptides from the apolipoproteins which would result in a rela-
tive overestimation of concentrations. However, overall QconCATs seem to be subjected to
fast and complete digestion [36]. Notwithstanding the differences in concentrations quantified,
QconCAT quantitation of Apo A-IV and C-II fall within their reference ranges, whereas Apo
A-II, B-100, C-III and E are less than a factor of 2 out of their reference ranges. Only the con-
centration of ApoA1 is more than a factor 2 out of the reference range. With HI3 quantitation,
Apo A-II, Apo E are less than a factor of 2 outside their reference range, while Apo C-II is
more than a factor two out of range. Overall, HI3 quantitation seems to be as close to reference
ranges in plasma as the QconCAT internal standard for the apolipoproteins detected (Fig 2b).
HI3 peptide quantitation: reliability
Reproducibility of HI3 peptide quantitation also determines the confidence with which results
can be interpreted. Using the protein concentrations determined for a single pooled plasma
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Fig 2. Quantitation of plasma protein concentrations by HI3, QconCAT and immunoassay. (a) Intra-assay variation of apolipoproteins by HI3 and
QconCAT on a single day of measurements. (b) Protein concentration quantified by HI3 peptide quantitation (squares) or QconCAT (circles) and their
reference ranges (grey boxes) in 5 pooled plasma samples. (c) Median HI3 peptide quantitation (squares) in 31 samples apart from fibrinogen (n = 30) and
complement C4 (n = 29), error bars indicate the minimal and maximum value measured in the plasma samples, while grey boxes indicate ranges quantified
by immunoassays in the same samples.
doi:10.1371/journal.pone.0140097.g002
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sample, the analytical variance (AV, Table 2) was calculated throughout 9 days of LCMSE mea-
surements (median 10%, range 4–212%). Intra-assay variation (IAV, Table 2) was determined
by 6 individual digestions of an aliquot of a pooled plasma sample and subsequent measure-
ments during 1 day (median 16%, range 6–64%). Inter-assay variability (IRV, Table 2) was
determined by thawing, digesting and measuring of a frozen aliquot of a pooled plasma sample
over 3 months of normal operation (median 19%, range 8–64%). Zhang et al. [44] showed that
median coefficients of variation (CVs) obtained using a single standard rather than individual
standards for each individual protein can be twice as high. Median intra-assay variability of
HI3 peptide quantitation is somewhat higher (Table 3) than those reported for targeted-studies
employing isotope-labelled standards [12, 13], but on a par with a targeted study that did not
use individual standards for each protein [14]. Overall the percentage of proteins that had an
intra-assay variation<20% and<30% was somewhat lower for HI3 peptide quantitation,
when compared to targeted studies that employ labelled standards (Table 3), while they were
similar to a targeted study not using isotope-labelled standards.
Comparing HI3 peptide with standard clinical immunoassay quantitation
We also compared the concentrations determined by HI3 peptide quantitation with those of
routine clinical immunoassays in the same sample set (31 samples), which are currently the
standard for plasma protein determination in clinical practice. For the 12 proteins tested, eight
concentrations determined by HI3 peptide quantitation fall within the range determined by
immunoassay in the same set, whereas three proteins are not more than a factor of two outside
of it (Fig 2c). Only in the case of complement C4 the concentration determined by LCMSE was
markedly outside the immunoassay range (see Table 4 and Fig 2c). Protein concentration data
obtained by LCMSE were also compared to those obtained by immunoassay in individual sam-
ples (Fig 3). Ordinary least squares linear regression reveals linear relationships. Spearman cor-
relation coefficients, allowing the detection of covariation in the assays, are given in Table 4.
The majority of protein concentrations determined by LCMSE showed good (r = 0.8–0.9) or
very good correlation (r>0.9) with immunoassays. In the case of three proteins correlation is
fair (>0.7). Reproducibility of immunoassays was found to be better for each of the 12 proteins
examined. The median inter assay variance for HI3 peptide quantitation was 19% (12–30%)
compared to 3% (1–5%) for immunoassays (Table 4).
Discussing the relevance of our findings for (semi)clinical settings
Our comparative study shows that using LCMSE and HI3 peptide quantitation, multiple
plasma proteins can be quantified in one run. We were able to quantify 59 individual plasma
Table 3. Intra-assay variation comparison of Hi3 peptide quantitation to targeted proteomics studies
of plasma proteins.
Source of Data Intra-assay CV CV 20% CV 30%
HI3 peptide quantitation data from this study. 16% (6–64%) 82% 90%
Targeted Proteomics study [12] using isotopic labels. 8% (7–12%) 100% 100%
Targeted Proteomics study [16] using isotopic labels. 6% (1–18%) 100% 100%
Targeted Proteomics study [15] using isotopic labels. 5% (1–20%) 100% 100%
Targeted Proteomics study [13] using isotopic labels. 9% (5–60%) 93% 98%
Targeted Proteomics study [14] without isotopic labels. 12% (5–40%) 76% 88%
Range of minimum to maximum value of the CV is shown between brackets.
doi:10.1371/journal.pone.0140097.t003
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proteins, however only 23 proteins were quantifiable in all samples measured with an inter-
assay variability 20%, (35 proteins inter-assay variability 30%). The time required for
quantitation is currently two hours per sample. This multiple-protein analysis takes somewhat
long compared to rapid analyses in single-protein immunoassays (~ 10 minutes), and also
compared with recent targeted-proteomics studies [15–18] measuring larger numbers of pro-
teins e.g. 142 proteins in ~47 minutes reported by Percy et al. [15].
We compared plasma protein concentrations determined by label free, HI3 peptide quantita-
tion to those determined by immunoassays and targeted studies from literature using isotope-
labelled standards. We also used LCMSE with spiked in isotopic standards for apolipoproteins.
Overall HI3 peptide quantitation determines plasma protein concentrations as well as other
mass spectrometric assays employing isotopic standards in relation to reference ranges from lit-
erature. Comparison of data obtained by LCMSE and immunoassay reveals a good correlation
between the two. With regard to correlation with immunoassays various targeted-studies [4–9]
report Spearman correlation coefficients from 0.43 to 0.99, which are for the most part compa-
rable to those reported here.
Regarding reproducibility, the targeted studies as well as HI3 peptide quantitation have a
higher variability than immunoassays used in diagnostic routine (Table 4). The low variability
of immunoassays is necessary in clinical routine where individual samples are assayed against a
known reference range. In comparison with targeted analysis however, variability is not much
higher, within 30% for most proteins: very useful for untargeted analysis of plasma samples in
discovery phases of clinical research.
In those cases where LCMSE gives results differing from those reported in literature or by
immunoassays it should be stressed that LCMSE detects tryptic fragments of proteins. LCMSE
uses these peptides as proxies to calculate amounts of intact proteins. In most cases proteins
Table 4. Comparison of quantification of abundant plasma proteins by HI3 peptide quantitation and clinical immunoassays.
Protein HI3 peptide quantitation Immunoassay r
median (ng/mL) intra-assay CV1(%) inter-assay CV2(%) n1 median (ng/mL) inter-assay CV3(%) n2
Albumin 7.4 x107 15 12 31 4.7 x107 2 31 0.72
Immunoglobulin γ 4.8 x106 17 30 31 9.6 x106 2 31 0.86
Transferrin 2.7 x106 19 19 31 2.7 x106 2 31 0.75
Fibrinogen 2.6 x106 15 14 30 1.6 x106 3 30 0.81*
Complement C3 2.3 x106 16 17 31 1.0 x106 2 31 0.86
Apolipoprotein A-I 1.7 x106 14 29 31 1.5 x106 4 31 0.86
Haptoglobin 1.3 x106 20 26 31 1.2 x106 2 31 0.92
Apolipoprotein B-100 1.0 x106 15 14 31 0.9 x106 3 31 0.85
Immunoglobulin α 0.7 x106 17 18 31 1.8 x106 1 31 0.93
Complement C4 0.7 x106 16 16 29 0.2 x106 3 31 0.76
Ceruloplasmin 0.4 x106 16 22 31 0.3 x106 5 31 0.89
Immunoglobulin μ 0.2 x106 14 26 31 1.0 x106 3 31 0.96
Median (ng/mL): median of protein concentrations determined from number of samples shown in column n1 or n2.Intra-assay CV1: coefficient of variation
by analysis of 6 aliquots of a pooled plasma sample, digested and injected during 1 day of measurements; Inter-assay CV2 by analysis of 7 aliquots of a
pooled sample, digested and injected during a period of 3 months of normal operation. n1, the number of samples with proteins quantified by LCMSE (out
of 31). Immunoassay data were obtained from the external quality control assessment scheme of the Stichting Kwaliteitscontrole Medische Laboratoria
(SKML) in the Netherlands, data from September 2010. Median concentration of each analyte, inter-institute variation (inter-assay CV3) and number of
samples in which a protein was detected (n2), are provided. r = Spearman correlation coefficient between label free MSe and immunoassay values
obtained for individual samples, * two outliers were removed, with outliers r = 0.54.
doi:10.1371/journal.pone.0140097.t004
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Fig 3. Correlation of concentrations obtained by either label free mass spectrometry or clinical immunoassay of 12 abundant plasma proteins.
Each dot represents the correlation between the protein concentration (g/L) of a single sample determined by clinical immunoassays (x-axis) and label free
mass spectrometry (y-axis). Regression lines (solid black) obtained by ordinary least squares linear regression and the formulas describing them are shown.
The dashed line, x = y, represents perfect correlation for comparison.
doi:10.1371/journal.pone.0140097.g003
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quantified by LCMSE tend to slightly underestimate concentrations in plasma compared to lit-
erature ranges (Fig 1c). Variation in digestion efficiency for proteins can affect quantitation
[35] and incomplete digestion would generally lead to underestimation of actual protein con-
centration. However, as can be deduced from S2 Fig and S2 Table, the proteins underestimated
are not specifically the ones increasing in quantitation with longer digestions or with more
trypsin added.
On the other hand, overestimation of protein amounts (e.g. in the case of serum albumin)
could be explained by the fact that some proteins in plasma may already be partially broken
down into fragments from which tryptic peptides can still be generated. More generally, this
phenomenon can be exacerbated under disease-conditions such as exemplified by Gaucher dis-
ease, where proteases in the circulation are abnormally high [45], and should be taken into
account when doing peptide level quantification. With immunoassays, concentrations of epi-
topes are determined; strictly speaking, epitope concentration does not have to correlate per-
fectly with concentrations of intact proteins either. This is exemplified by the results of the
external quality assessment of proteins in the Biorad NEQAS of March 12th 2012. In this
scheme, the lowest and highest mean results of the quality control samples differed between
(commercial, usually epitope-directed) antibody-based assays. Ceruloplasmin, haptoglobin,
complement factors 3 and 4, IgA, IgG and IgM differed by maximum factors of 1.20, 1.35, 1.26,
1.57, 1.23. 4.87 and 1.48-fold, respectively.
Conclusions
Our study demonstrates that LCMSE allows reproducible untargeted quantitation of abundant
plasma proteins. It gives fair to excellent correlation with immunoassays, and is achieved at
low setup costs, without costly isotope-labelled standards used in targeted proteomics
approaches. Reasonable variability compared to these targeted-approaches also gives confi-
dence with regard to using this method. Furthermore, its use in investigations employing non-
human model organisms with limited immunoassay availability is an attractive option. Diffi-
culties in multiplexing immunoassays [46] combined with high setup costs mean that, despite
longer analysis times, MS-based assays such as LCMSE can be of interest when measuring large
numbers of plasma proteins simultaneously. Although targeted approaches are more suited to
validate predetermined candidate-biomarker panels in large patient cohorts, especially in
plasma where targeted approaches can benefit from their larger dynamic range, the untargeted
nature of LCMSE and the ability to forego isotope-labelled standards still make it an attractive
tool in discovery studies in clinical research settings. Use of capillary flow liquid chromatogra-
phy as used in targeted studies (instead of nano-liquid chromatography) could bring down
analysis times for LCMSE as well, although larger sample amounts would be needed, which is
not a problem for human blood plasma, but can be a limiting factor in micro-dissected disease
tissues. Furthermore, addition of ion-mobility [47] as an extra dimension of separation of ions
before MSE detection has been shown to increase peptide and protein identification rates sub-
stantially Distler et al. [48] without increasing analysis time (as exemplified by quantitative
results for>2500 proteins in a 90 min gradient in 200 ug Hela cell digest).
Overall, reproducibility of quantitation of the LCMSE approach is acceptable for discovery
studies in a (clinical) research laboratory setting [49], provided appropriate reference ranges
are applied, taking into account biases of different techniques.
Supporting Information
S1 Fig. Linearity of HI3 peptide quantitation with increasing protein amount injected on
column. Dilutions of a plasma proteome digest were mixed with a fixed amount of ADH1
Plasma Protein Quantification by Mass Spectrometry
PLOS ONE | DOI:10.1371/journal.pone.0140097 October 16, 2015 17 / 22
digest standard and injected. The amount in ng quantified using HI3 peptide signals is shown
for 12 selected proteins.
(PDF)
S2 Fig. Digestion time series of a pooled plasma proteome sample. The digestion of a single
plasma sample was followed over 24 hours. HI3 peptide summed intensities were normalized
to the highest value measured in the time series for each protein
(PDF)
S3 Fig. Linearity of detection of individual peptides derived from QconCAT in a plasma
background. Increasing amounts of QconCAT added to a pooled plasma sample prior to
digestion. Ion intensities of identified peptides are plotted against the amount (fmols) added.
Formula and R2 obtained are depicted
(PDF)
S4 Fig. Reference concentrations of proteins identified by LCMSE. Average concentration
from Hortin et al. [42] is shown (grey dots), proteins identified by LCMS analysis are shown by
blue diamonds, proteins for which a quantitative value was also determined by HI3 peptide
quantitation are indicated by red squares.
(PDF)
S1 Table. PGLS 2.5 Hi3 protein quantitative data.
(XLSX)
S2 Table. Changes in ng protein quantified on column after digestion with different
amounts of trypsin.
(XLSX)
S3 Table. HI3 peptides in the injections as ranked by PLGS 2.5: number of injections in
which a peptide was detected, variance of peak area and retention time.
(XLSX)
S4 Table. Manually selected HI3Peptides: number of injections detected, variance of peak
area and retention time.
(XLSX)
S5 Table. 'Manual' versus 'automatic' peptide selection.
(XLSX)
S6 Table. Comparison of proteins quantified by Hi3 peptide quantitation in plasma to ref-
erence ranges and targeted studies of plasma proteins.
(XLSX)
S7 Table. Comparison of plasma proteins quantified by Hi3 peptide quantitation as well as
three targeted proteomics studies.
(XLSX)
S8 Table. QconCAT quantitation of apolipoproteins in 5 pooled plasma samples.
(XLSX)
S9 Table. Manually recalculated plasma protein concentrations of samples and reinjected
samples.
(XLSX)
S10 Table. Final manual HI3 and immunoassay quantitative data.
(XLSX)
Plasma Protein Quantification by Mass Spectrometry
PLOS ONE | DOI:10.1371/journal.pone.0140097 October 16, 2015 18 / 22
S11 Table. Protein identifications listed per sample.
(XLSX)
S12 Table. Results for apolipoproteins obtained from 5 pooled plasma samples using HI3
peptide or QconCAT based quantitation compared to literature reference ranges.
(XLSX)
S1 Text. Supplemental Materials and Methods.
(DOCX)
Acknowledgments
The authors wish to acknowledge the PRIDE Team for assistance in preparing the data of this
manuscript for the PRIDE public repository [50].
Author Contributions
Conceived and designed the experiments: GK JMFGA AS. Performed the experiments: GK
YW JPvS. Analyzed the data: GK ND JPvS JPCV YWDS. Contributed reagents/materials/anal-
ysis tools: YW RJB JPvS AS JIL JPCV. Wrote the paper: GK DS ND YW RJB JPvS AS JMFGA
JIL JPCV. Provided technical support during the mass-spectrometry measurements and
advised on data analysis, but did not have any undue influence in the study design, data collec-
tion and analysis, decision to publish, or preparation of the manuscript: JPCV JIL.
References
1. Parker CE, Pearson TW, Anderson NL, Borchers CH. Mass-spectrometry-based clinical proteomics—
a review and prospective. Analyst. 2010; 135(8):1830–8. Epub 2010/06/04. doi: 10.1039/c0an00105h
PMID: 20520858.
2. Pagel O, Loroch S, Sickmann A, Zahedi RP. Current strategies and findings in clinically relevant post-
translational modification-specific proteomics. Expert Rev Proteomics. 2015; 12(3):235–53. Epub
2015/05/09. doi: 10.1586/14789450.2015.1042867 PMID: 25955281; PubMed Central PMCID:
PMC4487610.
3. Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification, and validation—
quality assurance and control of protein biomarker assays. Mol Oncol. 2014; 8(4):840–58. Epub 2014/
04/10. doi: 10.1016/j.molonc.2014.03.006 S1574-7891(14)00054-4 [pii]. PMID: 24713096.
4. Agger SA, Marney LC, Hoofnagle AN. Simultaneous quantification of apolipoprotein A-I and apolipo-
protein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Clin Chem. 2010;
56(12):1804–13. Epub 2010/10/07. doi: clinchem.2010.152264 [pii] doi: 10.1373/clinchem.2010.
152264 PMID: 20923952.
5. Keshishian H, Addona T, Burgess M, Mani DR, Shi X, Kuhn E, et al. Quantification of cardiovascular
biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Prote-
omics. 2009; 8(10):2339–49. Epub 2009/07/15. doi: M900140-MCP200 [pii] doi: 10.1074/mcp.
M900140-MCP200 PMID: 19596694.
6. Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, et al. Developing multiplexed assays
for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass
spectrometry. Clin Chem. 2009; 55(6):1108–17. Epub 2009/04/18. doi: clinchem.2009.123935 [pii] doi:
10.1373/clinchem.2009.123935 PMID: 19372185.
7. Nicol GR, Han M, Kim J, Birse CE, Brand E, Nguyen A, et al. Use of an immunoaffinity-mass spectrom-
etry-based approach for the quantification of protein biomarkers from serum samples of lung cancer
patients. Mol Cell Proteomics. 2008; 7(10):1974–82. Epub 2008/04/05. doi: M700476-MCP200 [pii] doi:
10.1074/mcp.M700476-MCP200 PMID: 18388126.
8. Williams DK, Muddiman DC. Absolute quantification of C-reactive protein in human plasma derived
from patients with epithelial ovarian cancer utilizing protein cleavage isotope dilution mass spectrome-
try. J Proteome Res. 2009; 8(2):1085–90. Epub 2009/02/07. doi: 10.1021/pr800922p 10.1021/
pr800922p [pii]. PMID: 19196186.
9. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Quantification of thyroglobulin, a low-abundance
serum protein, by immunoaffinity peptide enrichment and tandemmass spectrometry. Clin Chem.
Plasma Protein Quantification by Mass Spectrometry
PLOS ONE | DOI:10.1371/journal.pone.0140097 October 16, 2015 19 / 22
2008; 54(11):1796–804. Epub 2008/09/20. doi: clinchem.2008.109652 [pii] doi: 10.1373/clinchem.
2008.109652 PMID: 18801935.
10. Hoofnagle AN, Becker JO, Oda MN, Cavigiolio G, Mayer P, Vaisar T. Multiple-reaction monitoring-
mass spectrometric assays can accurately measure the relative protein abundance in complex mix-
tures. Clin Chem. 2012; 58(4):777–81. Epub 2012/02/07. doi: clinchem.2011.173856 [pii] doi: 10.1373/
clinchem.2011.173856PMID: 22307200.
11. LassmanME, McLaughlin TM, Somers EP, Stefanni AC, Chen Z, Murphy BA, et al. A rapid method for
cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid
chromatography/tandemmass spectrometry. Rapid CommunMass Spectrom. 2011; 26(2):101–8.
Epub 2011/12/17. doi: 10.1002/rcm.5296PMID: 22173797.
12. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, et al. Multi-site assessment of
the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in
plasma. Nat Biotechnol. 2009; 27(7):633–41. Epub 2009/06/30. doi: nbt.1546 [pii] doi: 10.1038/nbt.
1546 PMID: 19561596.
13. Kuzyk MA, Smith D, Yang J, Cross TJ, Jackson AM, Hardie DB, et al. Multiple reaction monitoring-
based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics. 2009; 8
(8):1860–77. Epub 2009/05/05. doi: M800540-MCP200 [pii] doi: 10.1074/mcp.M800540-MCP200
PMID: 19411661.
14. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major
plasma proteins. Mol Cell Proteomics. 2006; 5(4):573–88. Epub 2005/12/08. doi: M500331-MCP200
[pii] doi: 10.1074/mcp.M500331-MCP200 PMID: 16332733.
15. Percy AJ, Chambers AG, Yang J, Hardie DB, Borchers CH. Advances in multiplexed MRM-based pro-
tein biomarker quantitation toward clinical utility. Biochim Biophys Acta. 2014; 1844(5):917–26. Epub
2013/06/29. doi: 10.1016/j.bbapap.2013.06.008 S1570-9639(13)00239-2 [pii]. PMID: 23806606.
16. Domanski D, Percy AJ, Yang J, Chambers AG, Hill JS, Freue GV, et al. MRM-based multiplexed quan-
titation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics. 2012; 12
(8):1222–43. Epub 2012/05/12. doi: 10.1002/pmic.201100568 PMID: 22577024.
17. Percy AJ, Chambers AG, Yang J, Borchers CH. Multiplexed MRM-based quantitation of candidate can-
cer biomarker proteins in undepleted and non-enriched human plasma. Proteomics. 2013; 13
(14):2202–15. Epub 2013/04/18. doi: 10.1002/pmic.201200316 PMID: 23592487.
18. Huttenhain R, Soste M, Selevsek N, Rost H, Sethi A, Carapito C, et al. Reproducible quantification of
cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med. 2012; 4
(142):142ra94. Epub 2012/07/13. doi: 10.1126/scitranslmed.3003989 4/142/142ra94 [pii]. PMID:
22786679; PubMed Central PMCID: PMC3766734.
19. Ishihama Y, Schmidt T, Rappsilber J, Mann M, Hartl FU, Kerner MJ, et al. Protein abundance profiling
of the Escherichia coli cytosol. BMCGenomics. 2008; 9:102. Epub 2008/02/29. doi: 10.1186/1471-
2164-9-102 1471-2164-9-102 [pii]. PMID: 18304323; PubMed Central PMCID: PMC2292177.
20. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein
abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of
sequenced peptides per protein. Mol Cell Proteomics. 2005; 4(9):1265–72. Epub 2005/06/17. doi:
M500061-MCP200 [pii] doi: 10.1074/mcp.M500061-MCP200PMID: 15958392.
21. Lu P, Vogel C, Wang R, Yao X, Marcotte EM. Absolute protein expression profiling estimates the rela-
tive contributions of transcriptional and translational regulation. Nat Biotechnol. 2007; 25(1):117–24.
Epub 2006/12/26. doi: nbt1270 [pii] doi: 10.1038/nbt1270PMID: 17187058.
22. Braisted JC, Kuntumalla S, Vogel C, Marcotte EM, Rodrigues AR, Wang R, et al. The APEXQuantita-
tive Proteomics Tool: generating protein quantitation estimates from LC-MS/MS proteomics results.
BMC Bioinformatics. 2008; 9:529. Epub 2008/12/11. doi: 10.1186/1471-2105-9-529 1471-2105-9-529
[pii]. PMID: 19068132; PubMed Central PMCID: PMC2639435.
23. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mam-
malian gene expression control. Nature. 2011; 473(7347):337–42. Epub 2011/05/20. doi: 10.1038/
nature10098 nature10098 [pii]. PMID: 21593866.
24. Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ. Absolute quantification of proteins by
LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics. 2006; 5(1):144–56. Epub 2005/10/13.
doi: M500230-MCP200 [pii] doi: 10.1074/mcp.M500230-MCP200 PMID: 16219938.
25. Nagaraj N, Wisniewski JR, Geiger T, Cox J, Kircher M, Kelso J, et al. Deep proteome and transcriptome
mapping of a human cancer cell line. Mol Syst Biol. 2011; 7:548. Epub 2011/11/10. doi: 10.1038/msb.
2011.81 msb201181 [pii]. PMID: 22068331; PubMed Central PMCID: PMC3261714.
26. Ning K, Fermin D, Nesvizhskii AI. Comparative analysis of different label-free mass spectrometry
based protein abundance estimates and their correlation with RNA-Seq gene expression data. J
Plasma Protein Quantification by Mass Spectrometry
PLOS ONE | DOI:10.1371/journal.pone.0140097 October 16, 2015 20 / 22
Proteome Res. 2012; 11(4):2261–71. Epub 2012/02/15. doi: 10.1021/pr201052x PMID: 22329341;
PubMed Central PMCID: PMC3744887.
27. Grossmann J, Roschitzki B, Panse C, Fortes C, Barkow-Oesterreicher S, Rutishauser D, et al. Imple-
mentation and evaluation of relative and absolute quantification in shotgun proteomics with label-free
methods. J Proteomics. 2010; 73(9):1740–6. Epub 2010/06/26. doi: 10.1016/j.jprot.2010.05.011
S1874-3919(10)00170-3 [pii]. PMID: 20576481.
28. Arike L, Valgepea K, Peil L, Nahku R, Adamberg K, Vilu R. Comparison and applications of label-free
absolute proteome quantification methods on Escherichia coli. J Proteomics. 2012; 75(17):5437–48.
Epub 2012/07/10. doi: 10.1016/j.jprot.2012.06.020 S1874-3919(12)00486-1 [pii]. PMID: 22771841.
29. Vissers JP, Langridge JI, Aerts JM. Analysis and quantification of diagnostic serummarkers and protein
signatures for Gaucher disease. Mol Cell Proteomics. 2007; 6(5):755–66. Epub 2007/02/13. doi:
M600303-MCP200 [pii] doi: 10.1074/mcp.M600303-MCP200 PMID: 17293593.
30. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of
Protein using Bicinchoninic Acid. Anal Biochem. 1985; 150:76–85. PMID: 3843705
31. Geromanos SJ, Vissers JP, Silva JC, Dorschel CA, Li GZ, Gorenstein MV, et al. The detection, correla-
tion, and comparison of peptide precursor and product ions from data independent LC-MS with data
dependant LC-MS/MS. Proteomics. 2009; 9(6):1683–95. Epub 2009/03/19. doi: 10.1002/pmic.
200800562 PMID: 19294628.
32. Martens L, Vandekerckhove J, Gevaert K. DBToolkit: processing protein databases for peptide-centric
proteomics. Bioinformatics. 2005; 21(17):3584–5. Epub 2005/07/21. doi: bti588 [pii] doi: 10.1093/
bioinformatics/bti588 PMID: 16030071.
33. Mertens BJ, De Noo ME, Tollenaar RA, Deelder AM. Mass spectrometry proteomic diagnosis: enacting
the double cross-validatory paradigm. J Comput Biol. 2006; 13(9):1591–605. Epub 2006/12/07. doi: 10.
1089/cmb.2006.13.1591 PMID: 17147482.
34. Brownridge PJ, Harman VM, Simpson DM, Beynon RJ. Absolute multiplexed protein quantification
using QconCAT technology. Methods Mol Biol. 2012; 893:267–93. Epub 2012/06/06. doi: 10.1007/
978-1-61779-885-6_18PMID: 22665307.
35. Proc JL, Kuzyk MA, Hardie DB, Yang J, Smith DS, Jackson AM, et al. A quantitative study of the effects
of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by
trypsin. J Proteome Res. 2010; 9(10):5422–37. Epub 2010/08/21. doi: 10.1021/pr100656u PMID:
20722421.
36. Brownridge P, Beynon RJ. The importance of the digest: proteolysis and absolute quantification in pro-
teomics. Methods. 2011; 54(4):351–60. Epub 2011/06/21. doi: S1046-2023(11)00097-1 [pii] doi: 10.
1016/j.ymeth.2011.05.005PMID: 21683145.
37. Leon IR, Schwammle V, Jensen ON, Sprenger RR. Quantitative assessment of in-solution digestion
efficiency identifies optimal protocols for unbiased protein analysis. Mol Cell Proteomics. 2013; 12
(10):2992–3005. Epub 2013/06/25. doi: 10.1074/mcp.M112.025585 M112.025585 [pii]. PMID:
23792921; PubMed Central PMCID: PMC3790306.
38. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome
analysis. Nat Methods. 2009; 6(5):359–62. Epub 2009/04/21. doi: 10.1038/nmeth.1322 nmeth.1322
[pii]. PMID: 19377485.
39. Manza LL, Stamer SL, Ham AJ, Codreanu SG, Liebler DC. Sample preparation and digestion for prote-
omic analyses using spin filters. Proteomics. 2005; 5(7):1742–5. Epub 2005/03/12. doi: 10.1002/pmic.
200401063 PMID: 15761957.
40. Fonslow BR, Stein BD, Webb KJ, Xu T, Choi J, Park SK, et al. Addendum: Digestion and depletion of
abundant proteins improves proteomic coverage. Nat Methods. 2014; 11(3):347–8. Epub 2014/04/12.
PMID: 24724171; PubMed Central PMCID: PMC4408018.
41. Fonslow BR, Stein BD, Webb KJ, Xu T, Choi J, Park SK, et al. Digestion and depletion of abundant pro-
teins improves proteomic coverage. Nat Methods. 2013; 10(1):54–6. Epub 2012/11/20. doi: 10.1038/
nmeth.2250 nmeth.2250 [pii]. PMID: 23160281; PubMed Central PMCID: PMC3531578.
42. Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of the human plasma proteome
comprising the top 4 logs of polypeptide abundance. Clin Chem. 2008; 54(10):1608–16. Epub 2008/08/
09. doi: clinchem.2008.108175 [pii]doi: 10.1373/clinchem.2008.108175 PMID: 18687737.
43. Rivers J, Simpson DM, Robertson DH, Gaskell SJ, Beynon RJ. Absolute multiplexed quantitative anal-
ysis of protein expression during muscle development using QconCAT. Mol Cell Proteomics. 2007; 6
(8):1416–27. Epub 2007/05/19. doi: M600456-MCP200 [pii]doi: 10.1074/mcp.M600456-
MCP200PMID: 17510050.
44. Zhang H, Liu Q, Zimmerman LJ, Ham AJ, Slebos RJ, Rahman J, et al. Methods for Peptide and protein
quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol Cell
Plasma Protein Quantification by Mass Spectrometry
PLOS ONE | DOI:10.1371/journal.pone.0140097 October 16, 2015 21 / 22
Proteomics. 2011; 10(6):M110 006593. Epub 2011/03/02. doi: M110.006593 [pii]doi: 10.1074/mcp.
M110.006593 PMID: 21357624.
45. van Breemen MJ, Aerts JM, Sprenger RR, Speijer D. Potential artefacts in proteome analysis of plasma
of Gaucher patients due to protease abnormalities. Clin Chim Acta. 2008; 396(1–2):26–32. Epub 2008/
07/22. doi: S0009-8981(08)00319-7 [pii]doi: 10.1016/j.cca.2008.06.018PMID: 18640107.
46. Ellington AA, Kullo IJ, Bailey KR, Klee GG. Antibody-based protein multiplex platforms: technical and
operational challenges. Clin Chem. 2010; 56(2):186–93. Epub 2009/12/05. doi: clinchem.2009.127514
[pii]doi: 10.1373/clinchem.2009.127514 PMID: 19959625.
47. Valentine SJ, Plasencia MD, Liu X, Krishnan M, Naylor S, Udseth HR, et al. Toward plasma proteome
profiling with ion mobility-mass spectrometry. J Proteome Res. 2006; 5(11):2977–84. Epub 2006/11/
04. doi: 10.1021/pr060232i PMID: 17081049.
48. Distler U, Kuharev J, Navarro P, Levin Y, Schild H, Tenzer S. Drift time-specific collision energies
enable deep-coverage data-independent acquisition proteomics. Nat Methods. 2014; 11(2):167–70.
Epub 2013/12/18. doi: 10.1038/nmeth.2767nmeth.2767 [pii]. PMID: 24336358.
49. Carr SA, Abbatiello SE, Ackermann BL, Borchers C, Domon B, Deutsch EW, et al. Targeted peptide
measurements in biology and medicine: best practices for mass spectrometry-based assay develop-
ment using a fit-for-purpose approach. Mol Cell Proteomics. 2014; 13(3):907–17. Epub 2014/01/21.
doi: 10.1074/mcp.M113.036095M113.036095 [pii]. PMID: 24443746; PubMed Central PMCID:
PMC3945918.
50. Vizcaino JA, Cote RG, Csordas A, Dianes JA, Fabregat A, Foster JM, et al. The PRoteomics IDEntifica-
tions (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2013; 41(Database
issue):D1063–9. Epub 2012/12/04. doi: gks1262 [pii]doi: 10.1093/nar/gks1262PMID: 23203882.
Plasma Protein Quantification by Mass Spectrometry
PLOS ONE | DOI:10.1371/journal.pone.0140097 October 16, 2015 22 / 22
